•  EN 
  • Employee login

Real world studies in PharmacoEpidemiology, -Genetics, -Economics, &-Therapy (PEGET)

Print 

​​​​​​​​​​​​​​​​​​​​​​​​​​​​PEGET contributes to personalized medicine through development, validation and application of innovative data methodologies as well as ​“real world” assessments to study outcomes of pharmaceutical interventions and their implementation in daily practice. In particular, “Big” healthcare data from existing large prescription, healthcare and trial databases as well as from smaller population- or practice-based patient cohorts are used.

PEGET is a multidisciplinary group with roots in the Groningen Research Institute of Pharmacy (GRIP) and the University Medical Center Groningen (UMCG). Main research fields are: pharmacoepidemiology, pharmacogenetics, pharmacotherapy and precision drug therapy, quality of drug use, pharmacovigilance and pharmaco-economics.

Scientific and Societal output  

See PEGET on rug.nl

To be published soon.

Dissertations  

See Dissertations of PEGET on horafinita.nl

To be published soon.

Principal Investigators   Programme Leaders   Description of the programme  

PEGET is a multidisciplinary group with roots in the Groningen Research Institute of Pharmacy and the University Medical Center Groningen. Main research fields are: pharmacoepidemiology, pharmacogenetics, pharmacotherapy and precision drug therapy, quality of drug use, pharmacovigilance and pharmaco-economics. Within these fields, the following research themes and projects are currently distinguished and represent the focus of the program:

1. Optimizing the efficiency and quality of pharmaceutical interventions

  1. Assessments of the use of medicines in real world settings with a strong focus on multifactorial diseases and multi-morbidities, in particular in the context of optimal prescribing, dispensing and adherence; 
  2. Monitoring of medication safety and management of medication errors in clinical practice, specifically in vulnerable patient groups;
  3. Conduct of epidemiological and observational studies, including genetics, metabolomics, clinical and behavioral determinants, with healthcare databases to enhance personalized and stratified treatment;
  4. Conduct of specifically designed RCTs and pragmatic studies to evaluate new and existing pharmaceutical interventions and policies, including regulatory measures, to further enhance the quality of pharmaceutical care and develop best practices;
  5. Conduct of studies to assess cost-effectiveness of drugs and vaccination programs, also in relation to patient preferences and personalized treatment strategies.

2. Development, validation and application of advanced methodologies to generate scientific knowledge on determinants and effects of interventions in routine medical practice as well as to support policy making.

  1. Research into causal and subgroup methodologies using observational individual and aggregated patient information by use of Big data stored in large databases, such as IADB.nl, Eurocat, GIANTT, LifeLines, Lareb/VigiBase (WHO), DIAMETRIC, PHAMOUS, VIPP, CPRD, RNG, Vektis, UK-Biobank;
  2. Development of bias-adjustment and prediction techniques in Individual Patient Data analyses, meta-analyses and mixed-treatment comparisons;
  3. Development and application of new methodologies to estimate adherence (initiation, implementation and persistence) to multiple medications;
  4. Development of pharmaco-economic and risk-benefit models combining data from various sources

As part of the PEGET research program, “real world” data from prescription, healthcare and trial databases are maintained. Research takes advantage of the presence of the unique stable population of the Northern provinces of the Netherlands. We aim to stabilize and further increase the funding for “Big Pharmaceutical Data laboratories” and strengthen our grant positions by joint research projects, notably with other more clinically-oriented groups from GUIDE. We also aim to conduct studies with practice-based researchers, including (hospital) pharmacists and primary care practitioners. The ageing of the population and the vast and accruing possibilities for pharmaceutical interventions – both curative and preventive – pose challenges that cover a broad range of research and policy sectors. This requires collaborations beyond the PEGET or GUIDE structures, for example, within the Faculty FSE broader theme Data Science and Systems Complexity, and with agencies such as the Dutch Medicines Evaluation Board (CBG-MEB) and the Dutch Pharmacovigilance center (LAREB), as well as with partners in practice (e.g. other hospitals, professional and patient organizations). Also, we collaborate in EU-funded projects, such as UNISEC, PROMINENT, PRONKJEWAIL, and the Collaborative Groningen-Tomsk Pharmacogenotyping project.

Mission  

The mission of PEGET is to contribute to personalized medicine through development, validation and application of innovative data methodologies as well as “real world” assessments to study outcomes of pharmaceutical interventions and their implementation in daily practice. In particular, “Big” healthcare data from existing large prescription, healthcare and trial databases as well as from smaller population- or practice-based patient cohorts are used.
Aim is to further expand scientific knowledge on determinants of medicine use, and on their effects in clinical practice on population and individual level. Findings will support pharmaceutical decision-making from clinical drug development stage, regulatory approval, reimbursement  to finally optimal medicine use. Ultimately, this will contribute to improved health-related quality of life of our ageing population and make pharmaceutical healthcare more efficient and sustainable.

Relevance to Healthy Ageing  

The PEGET research program focuses on prevention and treatment of disease by medicines, including drugs and vaccines, considering effects on quality of life and costs, clinical management of drug therapy and drug safety, all explicitly as part of healthy ageing. Emphasis is on pharmaceutical treatments through all stages of life from reproduction phase through phases of multi-factorial diseases and old age as well as primary prevention of diseases.